-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Gilead Sciences, Raises Price Target to $200

Benzinga·10/30/2026 10:26:02
Needham analyst Joseph Stringer maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $170 to $200.